Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

SunTen Phytotech

Explore full profile

An herbal-based biotechnology company, develops botanical medicines and functional dietary products

New Taipei, TaiwanFounded 2001Biotech & Life Sciences
Valuation $50–100M Last recorded · 2006
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for SunTen Phytotech and the history behind them.

About SunTen Phytotech

SunTen Phytotech, established in 2000, operates as a subsidiary of the Sun Ten Pharmaceutical Group, focusing on the development of new botanical drugs. The parent company, Sun Ten Pharmaceutical, was founded in Taiwan in 1946 by Dr. Hon-yen Hsu. Dr. Hsu, recognized as the “Father of Scientific Chinese Herbal Medicine,” applied modern extraction technologies to Traditional Chinese Medicine (TCM). His background includes a PhD in Pharmacy from Kyoto University and a role as the director of Taiwan's Bureau of Drug Control, where he established standards to safeguard consumer health.

SunTen Phytotech was created to spearhead the group's entry into the biotech era, developing herbal-based products to meet specific medical needs. The company's work involves producing novel botanical medicines and functional dietary products aimed at addressing conditions like cardiovascular diseases and chronic gastrointestinal disorders. A notable milestone for SunTen Phytotech includes receiving a grant from Taiwan's Ministry of Economic Affairs in 2002 for the development of a new cardiovascular botanical drug, SB221. The company also secured an Industry Innovation Performance Award from the same ministry in 2008.

The business operates within the biotechnology and pharmaceutical markets, functioning as a research and development arm of the Sun Ten Group. Its business model revolves around the scientific development and clinical validation of botanical drugs, with some projects advancing to clinical trial stages. For instance, in 2001, the company collaborated with PhytoCeutica Co. in the US on an anti-cancer auxiliary drug and was contracted by Phytopharm Inc. in the UK to manufacture a plant-based product for canine skin and coat health. SunTen Phytotech leverages the broader group's extensive manufacturing capabilities, which are GMP, TGA, and PIC/S certified, ensuring high-quality production standards. The company's products are part of a larger portfolio that includes traditional herbal formulas, single herbs, and over-the-counter health foods, which are distributed globally through partners in the USA, Canada, Europe, and Asia.

Source: Dealroom company data

At a glance

Status
Closed
Founded
2001
Headquarters
New Taipei, Taiwan
Employees
30
Open positions
None listed
Dealroom signal
0.0/100
Industry
Health, Wellness Beauty
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Dietary Supplements, Biotechnology, Drug Development, Gastroenterology, Botanical, Botanical Medicines, Hard Tech, DT and LS
Business model
Manufacturing
Client focus
b2c
Investment activity
1 company, latest Dec 2006
Capital deployed
$10M
Preferred round
SERIES B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Dec 2006 $10M $40M SunTen Phytotech —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

SunTen Phytotech website traffic

Latest recorded traffic for SunTen Phytotech is 110 monthly website visits. SunTen Phytotech's team grew 42.9% over the past year.

Latest monthly visits110 1-year team growth+42.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • SunTen Phytotech
Employees 30 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇹🇼 Taiwan69.2%
🇨🇳 China7.7%
🇦🇺 Australia7.7%
🇲🇾 Malaysia7.7%
🇺🇸 United States7.7%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about SunTen Phytotech on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See SunTen Phytotech’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.